Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00517361 · ClinicalTrials.gov registry record · Phase 2
Phase II Study of Carboplatin and Bevacizumab (Avastin) for ER Neg, PR Neg, and HER2/Neu Neg Metastatic Breast Cancer
A Phase 2 study, sponsored by University of Chicago.
- Terminated
- Registry status
- Phase 2
- Development phase
- 11
- Enrollment target
NCT00517361 is a Phase 2 study that was terminated before completion, run by University of Chicago. The registered enrollment target is 11 participants.
The verdict
NCT00517361, a Phase 2 study, was terminated before completion, sponsored by University of Chicago.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 11 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the progression free survival (PFS) of metastatic ER, PR and HER2/neu negative breast cancers to the combination of carboplatin and bevacizumab (Avastin®) therapy.
Interventions
- DRUG carboplatin
- DRUG bevacizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2007-08 |
| Est. Completion | 2012-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00517361
The ClinicalTrials.gov registry entry for NCT00517361 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which carboplatin is the first listed.
NCT00517361 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00517361 about?
NCT00517361 is a clinical study titled "Phase II Study of Carboplatin and Bevacizumab (Avastin) for ER Neg, PR Neg, and HER2/Neu Neg Metastatic Breast Cancer". The purpose of this study is to determine the progression free survival (PFS) of metastatic ER, PR and HER2/neu negative breast cancers to the combination of carboplatin and bevacizumab (Avastin®) therapy.
What is the current status of trial NCT00517361?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 11 participants. The study started on 2007-08. Estimated completion is 2012-04.
What interventions are being tested in trial NCT00517361?
The interventions under investigation include: carboplatin (DRUG), bevacizumab (DRUG).
Who is sponsoring clinical trial NCT00517361?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.